COCH
Envoy Medical, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.72
▼ 0.03 (4.50%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.75
Prev close
0.75
Day high
0.75
Day low
0.73
Volume
60.43K
Market cap
—
P/E (TTM)
—
52W range
0.36 – 1.89
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-6.25%
-4.9%
1M
+13.46%
+9.7%
3M
+2.32%
-0.8%
6M
+5.63%
-5.4%
YTD
+13.46%
+1.2%
1Y
-40.94%
-60.9%
3Y
-92.73%
-166.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $241.00K | $225.00K | $316.00K | $237.00K | +7.1% |
| Operating revenue | $241.00K | $225.00K | $316.00K | $237.00K | +7.1% |
| Cost of revenue | $874.00K | $742.00K | $789.00K | $498.00K | +17.8% |
| Gross profit | -$633.00K | -$517.00K | -$473.00K | -$261.00K | -22.4% |
| Research & development | $12.49M | $10.18M | $8.96M | $4.97M | +22.7% |
| Selling, general & admin | $9.15M | $8.56M | $8.93M | $3.47M | +6.9% |
| Total operating expense | $21.64M | $18.74M | $17.89M | $8.45M | +15.5% |
| Operating income | -$22.27M | -$19.26M | -$18.36M | -$8.71M | -15.7% |
| Net interest income | -$1.59M | -$816.00K | $0 | — | -94.9% |
| Pre-tax income | -$23.76M | -$20.80M | -$29.92M | -$15.92M | -14.2% |
| Net income | -$23.76M | -$20.80M | -$29.92M | -$15.92M | -14.2% |
| Net income to common | -$28.66M | -$27.97M | -$31.27M | -$15.92M | -2.5% |
| Basic EPS | -1.23 | -1.49 | -2.54 | -1.57 | +17.4% |
| Diluted EPS | -1.23 | -1.49 | -2.54 | -1.57 | +17.4% |
| EBIT | -$22.17M | -$19.98M | -$29.92M | -$8.71M | -10.9% |
| EBITDA | -$21.86M | -$19.81M | -$29.79M | -$8.63M | -10.4% |
| Basic shares | 23.26M | 18.79M | 12.30M | 10.15M | +23.8% |
| Diluted shares | 23.26M | 18.79M | 12.30M | 10.15M | +23.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.74M | $5.48M | $4.22M | $183.00K | — | -31.8% |
| Cash & short-term investments | $3.74M | $5.48M | $4.22M | $183.00K | — | -31.8% |
| Accounts receivable | $34.00K | $38.00K | $70.00K | $41.00K | — | -10.5% |
| Inventory | $1.55M | $1.71M | $1.40M | $1.29M | — | -9.5% |
| Total current assets | $6.28M | $8.90M | $7.46M | $1.65M | — | -29.4% |
| Property, plant & equipment | $1.92M | $2.15M | $815.00K | $908.00K | — | -10.8% |
| Total assets | $8.56M | $11.54M | $8.27M | $2.56M | — | -25.8% |
| Total current liabilities | $11.56M | $7.54M | $7.29M | $2.52M | — | +53.4% |
| Current debt | — | — | — | $448.00K | — | — |
| Long-term debt | — | $18.72M | — | $33.40M | $23.48M | — |
| Total debt | $919.00K | $19.66M | $562.00K | $34.53M | — | -95.3% |
| Total liabilities | $20.32M | $30.38M | $10.05M | $38.75M | — | -33.1% |
| Retained earnings | -$313.40M | -$284.73M | -$257.26M | -$225.99M | — | -10.1% |
| Shareholder equity | -$11.77M | -$18.84M | -$1.78M | -$36.20M | — | +37.5% |
| Working capital | -$5.28M | $1.36M | $171.00K | -$871.00K | — | -489.0% |
| Net tangible assets | -$11.77M | -$18.84M | -$1.78M | -$36.20M | — | +37.5% |
| Shares issued | 28.93M | 21.33M | 19.60M | 19.55M | — | +35.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$23.76M | -$20.80M | -$29.92M | -$15.92M | -14.2% |
| Depreciation & amortisation | $302.00K | $173.00K | $133.00K | $75.00K | +74.6% |
| Stock-based compensation | $745.00K | $562.00K | $1.57M | $0 | +32.6% |
| Change in working capital | $1.84M | -$638.00K | -$983.00K | -$160.00K | +388.2% |
| Operating cash flow | -$18.20M | -$17.95M | -$17.09M | -$8.80M | -1.4% |
| Capital expenditure | -$179.00K | -$980.00K | -$153.00K | -$218.00K | +81.7% |
| Investing cash flow | -$179.00K | -$980.00K | -$153.00K | -$218.00K | +81.7% |
| Dividends paid | -$1.82M | -$2.45M | $0 | — | +25.7% |
| Financing cash flow | $16.63M | $20.20M | $21.28M | $8.09M | -17.7% |
| Free cash flow | -$18.38M | -$18.93M | -$17.24M | -$9.02M | +2.9% |
| End cash position | $3.74M | $5.48M | $4.22M | $183.00K | -31.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $39.00K | $75.00K | $42.00K | $78.00K | $46.00K | -48.0% |
| Operating revenue | $39.00K | $75.00K | $42.00K | $78.00K | $46.00K | -48.0% |
| Cost of revenue | $313.00K | $211.00K | $203.00K | $234.00K | $226.00K | +48.3% |
| Gross profit | -$274.00K | -$136.00K | -$161.00K | -$156.00K | -$180.00K | -101.5% |
| Research & development | $3.64M | $4.55M | $2.70M | $2.48M | $2.75M | -20.0% |
| Selling, general & admin | $2.04M | $1.70M | $2.85M | $2.43M | $2.18M | +20.5% |
| Total operating expense | $5.68M | $6.25M | $5.55M | $4.91M | $4.93M | -9.0% |
| Operating income | -$5.96M | -$6.38M | -$5.71M | -$5.07M | -$5.11M | +6.7% |
| Net interest income | $0 | $0 | -$471.00K | -$624.00K | -$495.00K | — |
| Pre-tax income | -$4.35M | -$6.59M | -$6.48M | -$5.69M | -$5.00M | +33.9% |
| Net income | -$4.35M | -$6.59M | -$6.48M | -$5.69M | -$5.00M | +33.9% |
| Net income to common | -$5.70M | -$7.74M | -$7.75M | -$6.94M | -$6.24M | +26.3% |
| Basic EPS | -0.08 | — | -0.35 | -0.32 | -0.29 | — |
| Diluted EPS | -0.08 | — | -0.35 | -0.32 | -0.29 | — |
| EBIT | -$4.35M | -$6.59M | -$6.01M | -$5.07M | -$4.50M | +33.9% |
| EBITDA | -$4.28M | -$6.51M | -$5.93M | -$4.98M | -$4.44M | +34.2% |
| Basic shares | 68.93M | — | 21.85M | 21.38M | 21.33M | — |
| Diluted shares | 68.93M | — | 21.85M | 21.38M | 21.33M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25.25M | $3.74M | $3.56M | $5.29M | $5.31M | — | +575.3% |
| Cash & short-term investments | $25.25M | $3.74M | $3.56M | $5.29M | $5.31M | — | +575.3% |
| Accounts receivable | $31.00K | $34.00K | $35.00K | $43.00K | $42.00K | — | -8.8% |
| Inventory | $1.49M | $1.55M | $1.64M | $1.59M | $1.66M | — | -3.6% |
| Total current assets | $27.68M | $6.28M | $5.76M | $7.51M | $8.31M | — | +340.9% |
| Property, plant & equipment | $1.81M | $1.92M | $2.03M | $1.96M | $2.07M | — | -5.5% |
| Total assets | $29.82M | $8.56M | $8.18M | $9.90M | $10.38M | — | +248.5% |
| Total current liabilities | $12.21M | $11.56M | $8.99M | $8.00M | $7.59M | — | +5.6% |
| Long-term debt | — | — | — | $27.93M | $23.11M | $18.72M | — |
| Total debt | $889.00K | $919.00K | $946.00K | $28.83M | $24.03M | — | -3.3% |
| Total liabilities | $19.27M | $20.32M | $15.71M | $39.76M | $34.61M | — | -5.2% |
| Retained earnings | -$319.10M | -$313.40M | -$305.66M | -$297.91M | -$290.97M | — | -1.8% |
| Shareholder equity | $10.55M | -$11.77M | -$7.53M | -$29.86M | -$24.22M | — | +189.7% |
| Working capital | $15.47M | -$5.28M | -$3.23M | -$487.00K | $717.00K | — | +392.8% |
| Net tangible assets | $10.55M | -$11.77M | -$7.53M | -$29.86M | -$24.22M | — | +189.7% |
| Shares issued | 76.88M | 28.93M | 23.81M | 21.52M | 21.33M | — | +165.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.35M | -$6.59M | -$6.48M | -$5.69M | -$5.00M | +33.9% |
| Depreciation & amortisation | $73.00K | $80.00K | $76.00K | $85.00K | $61.00K | -8.8% |
| Stock-based compensation | $283.00K | $115.00K | $324.00K | $146.00K | $160.00K | +146.1% |
| Change in working capital | -$758.00K | $78.00K | $762.00K | $77.00K | $922.00K | -1,071.8% |
| Operating cash flow | -$6.06M | -$5.68M | -$4.33M | -$4.46M | -$3.73M | -6.6% |
| Capital expenditure | — | -$172.00K | — | -$1.00K | -$6.00K | — |
| Investing cash flow | $0 | -$172.00K | $0 | -$1.00K | -$6.00K | +100.0% |
| Dividends paid | $0 | $1.00K | $0 | -$607.00K | -$1.21M | -100.0% |
| Financing cash flow | $27.57M | $6.04M | $2.60M | $4.44M | $3.55M | +356.5% |
| Free cash flow | -$6.06M | -$5.86M | -$4.33M | -$4.46M | -$3.73M | -3.5% |
| End cash position | $25.25M | $3.74M | $3.56M | $5.29M | $5.31M | +575.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.75
-4.20% from price
SMA 20
0.71
+5.42% from price
SMA 50
0.70
+7.05% from price
SMA 100
0.69
+3.60% from price
SMA 200
0.70
+7.17% from price
EMA 12
0.74
-2.59% from price
EMA 26
0.72
-0.39% from price
EMA 50
0.71
+1.22% from price
RSI (14)
55.8
Neutral
MACD (12,26,9)
0.02
Hist 0.00
ATR (14)
0.04
5.90% of price
Realised vol 30D
66.8%
Annualised
Bollinger upper
0.79
20, 2σ
Bollinger lower
0.63
20, 2σ
50 / 200 cross
Golden
0.70 vs 0.70
Trend bias
Above 200
+7.17%
Risk profile
Beta vs SPY
1.01
More volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
66.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-75.5%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
0.04
5.90% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Zacks · 1d ago
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 12d ago
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
TMX Newsfile · 13d ago
Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks · 30d ago
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
TMX Newsfile · 33d ago
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant
Benzinga · 33d ago
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
TMX Newsfile · 40d ago
EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results
Benzinga · 40d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.